BioCentury
ARTICLE | Clinical News

Brilacidin-OM: Phase II started

June 15, 2015 7:00 AM UTC

Cellceutix began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate Brilacidin-OM oral rinse thrice daily for up to 7 weeks in 60 patients with head and neck cancer undergoing chemora...